ARTICLE | Company News
Bio-Discovery, ZymoGenetics deal
October 11, 1999 7:00 AM UTC
ZymoGenetics, a wholly-owned subsidiary of Novo Nordisk
A/S (Bagsvaerd, Denmark), will have a one year exclusive option period to evaluate Bio-Discovery's B-D001 complement inhibitor, which is in preclinical development to prevent reperfusion injury in myocardial infarction and stroke. Bio-Discovery received an upfront fee for the option. ...